Remember that Pfizer co-owns Eliquis
BMS and Pfizer co-developed Eliquis and share profits and losses on a 40/60 basis, respectively. The U.S. Food and Drug Administration approved the first generics for Eliquis in December 2019. Eliquis (apixaban) is an oral Factor Xa inhibitor.
Sales of blood thinner Eliquis came in at $1.35 billion, a 19% increase on the third quarter of last year, due in part to continued adoption in non-valvular atrial fibrillation and oral anti-coagulant market share gains.
Remember that Pfizer co-owns Eliquis
>BMS and Pfizer co-developed Eliquis and share profits and losses on a 40/60 basis, respectively. The U.S. Food and Drug Administration approved the first generics for Eliquis in December 2019. Eliquis (apixaban) is an oral Factor Xa inhibitor.
>Sales of blood thinner Eliquis came in at $1.35 billion, a 19% increase on the third quarter of last year, due in part to continued adoption in non-valvular atrial fibrillation and oral anti-coagulant market share gains.
Patriot, excellent reminder. Thank you.
Patriot, excellent reminder. Thank you.
(post is archived)